Immediate improvement in pain relief Number of participants improved (good/very good efficacy) on a self assessed categorical 'overall efficacy score' (0 = no efficacy to 4 = very good) · patients with trigeminal neuralgia
Tizanidine showed no clear difference in immediate improvement in pain relief Number of participants improved… compared with carbamazepine (low certainty).
1 finding from 1 review
Relief of pain · patients with trigeminal neuralgia
1 finding from 1 review
Reduction in pain intensity · patients with trigeminal neuralgia
1 finding from 1 review
Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia
1 finding from 1 review
Adverse effects The number of participants with adverse effects · patients with trigeminal neuralgia
1 finding from 1 review
Reduction in pain intensity · patients with trigeminal neuralgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects (not reported) · patients with trigeminal neuralgia
1 finding from 1 review
Relief of pain · patients with trigeminal neuralgia
1 finding from 1 review
Reduction in pain intensity · patients with trigeminal neuralgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects · patients with trigeminal neuralgia
1 finding from 1 review
Time to treatment withdrawal · people with epilepsy
VGB showed no clear difference in time to treatment withdrawal compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Time to achieve 6‐month remission after the first 6 weeks of dose stabilisation from randomisation · people with epilepsy
It is very uncertain whether VGB changes time to achieve 6‐month remission after the first 6 weeks of dose… compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
Time to first seizure (post‐randomisation) All participants Range of · people with epilepsy
VGB may leads to higher time to first seizure after randomisation compared with CBZ monotherapy (low certainty).
1 finding from 1 review
Adverse events Visual field defects · people with epilepsy
It is very uncertain whether VGB changes adverse events Visual field defects compared with CBZ monotherapy (very low certainty).
1 finding from 1 review
Intervention not reported
"Substantial" benefit At least 50% reduction in pain or equivalent · adults with neuropathic pain (Trigeminal neuralgia, painful diabetic neuropathy, chronic post stroke pain)
The intervention may leads to higher "Substantial" benefit At least 50% reduction in pain or equivalent (low certainty).
1 finding from 1 review
Intervention not reported
"Moderate" benefit At least 30% reduction in pain · adults with neuropathic pain (Trigeminal neuralgia, painful diabetic neuropathy, chronic post stroke pain)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Proportion below 30/100 mm on VAS · adults with neuropathic pain (Trigeminal neuralgia, painful diabetic neuropathy, chronic post stroke pain)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Patient Global Impression of Change much or very much improved · adults with neuropathic pain (Trigeminal neuralgia, painful diabetic neuropathy, chronic post stroke pain)
1 finding from 1 review
no estimate extracted
Studies not reported
Very low